Breaking Finance News

Intellia Therapeutics Inc (NASDAQ:NTLA) has been upgraded to Hold in a report by Zacks Investment Research today.

Just yesterday Intellia Therapeutics Inc (NASDAQ:NTLA) traded -3.89% lower at $18.70. Intellia Therapeutics Inc’s 50-day moving average is $20.17 and its 200-day moving average is $22.36. The last stock price is down -22.64% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has decreased -0.01% over the same time period. 290,449 shares of NTLA traded hands, up from an average trading volume of 248,412

Zacks Investment Research has upgraded Intellia Therapeutics Inc (NASDAQ:NTLA) to Hold in a report released on 9/22/2016.

Recent Performance Chart

Intellia Therapeutics Inc (NASDAQ:NTLA)

Intellia Therapeutics Inc has with a one year low of $17.05 and a one year high of $30.40 and has a market cap of $0.

General Information About Intellia Therapeutics Inc (NASDAQ:NTLA)

Intellia Therapeutics, Inc. is a United States-based genome editing company focused on the development of curative therapeutics using a biological tool, CRISPR/Cas9 system. The Company's CRISPR/Cas9 technology edits diseased genes in the human body through a single treatment course. It focuses on the therapeutic applications of CRISPR/Cas9 genome editing. Its portfolio includes CRISPR/Cas9 platform technology, delivery technologies and nucleic acid modifications for human therapeutic use. The Company's CRISPR/Cas9 platform components include the guide ribonucleic acid (RNA) and the Cas9 nuclease (the genetic scissors). It has access to various delivery modalities specific to various in vivo and ex vivo approaches. The Company focuses on engineering ex vivo CRISPR/Cas9 cell therapies for chimeric antigen receptor T cell (CAR-T) and hematopoietic stem cell (HSC) applications. It also focuses on the use of in vivo Lipid Nanoparticle (LNP) delivery technology.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *